Alterity Therapeutics (ATHE) Stock Statistics & Valuation Metrics

Alterity Therapeutics has a market cap or net worth of $78.54M. The enterprise value is $105.10M.

Alterity Therapeutics has 15,345,617 shares outstanding. The number of shares has decreased by -2.65% in one year.

Alterity Therapeutics’s return on equity (ROE) is -1.39 and return on invested capital (ROIC) is -140.78%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Alterity Therapeutics had revenue of 4.02M and earned -19.12M in profits. Earnings per share was -3.12.

In the last 12 months, operating cash flow was -16.47M and capital expenditures 278.00, giving a free cash flow of -16.47M billion.

Alterity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Alterity Therapeutics upcoming earnings date is Feb 26, 2026, TBA (Confirmed).

Alterity Therapeutics as a current ratio of 3.54, with Debt / Equity ratio of 1.36%

In the past 12 months, Alterity Therapeutics has paid 46.09K in taxes.

Alterity Therapeutics EV to EBITDA ratio is -503.22, with an EV/FCF ratio of -780.94.

Alterity Therapeutics has $4.54M in cash and marketable securities with AU$105.83K in debt, giving a net cash position of -$4.43M billion.

Gross margin is 96.32%, with operating margin of -487.69%, and net profit margin of -475.79%.

The average price target for Alterity Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Hold